Objective: To evaluate the role of synovial oxidative stress on joint pathology in a spontaneous mouse model of osteoarthritis (OA) by intra-articular (IA) delivery of recombinant adeno-associated virus (rAAV) expressing anti-oxidant protein heme oxygenase-1 (HO-1). Methods: Joint transduction by rAAV vectors was evaluated with serotype 1, 2, 5 and 8 capsids carrying LacZ gene administered by IA injections into STR/ort mice. Transduced cell types were identified by b-galactosidase staining in sectioned joints. Effect of oxidative stress on AAV transduction of primary synoviocytes in vitro was quantitated by fluorescence-activated cell sorting (FACS) analysis. In vivo, the efficacy of rAAV1/ HO-1 was tested by IA administration into STR/ort mice followed by histopathological scoring of cartilage. Levels of 3-nitrotyrosine (3-NT) and HO-1 were assessed by immunohistochemistry (IHC) of joint sections. Results: Administration of a rAAV1 based vector into OA mouse joints resulted in transduction of the synovium, joint capsule, adipocytes and skeletal muscle while none of the serotypes showed significant cartilage transduction. All OA joints exhibited significantly elevated levels of oxidative stress marker, 3-NT, in the synovium compared to OA-resistant CBA-strain of mice. In vitro studies demonstrated that AAV transgene expression in primary synoviocytes was augmented by oxidative stress induced by H 2 O 2 and that a rAAV expressing HO-1 reduced the levels of oxidative stress. In vivo, HO-1 was increased in the synovium of STR/ort mice. However, delivery of rAAV1/HO-1 into OA joints did not reduce cartilage degradation. Conclusions: AAV-mediated HO-1 delivery into OA joints during active disease was not sufficient to improve cartilage pathology in this model.
Introduction
Osteoarthritis (OA) is a painful joint disease characterized by cartilage degradation, mild synovial inflammation and changes in bone, ligaments and tendons 1, 2 . Currently treatment consists of pain management as there are no clinically approved disease modifying agents. Therapeutics that can be delivered directly into the joint space offer the advantage of providing a high local concentration at the disease site while reducing the potential for adverse effects often associated with systemic delivery. Viral vectors such as adeno-associated virus (AAV) delivered into the intra-articular (IA) joint space can allow local production of therapeutics from transduced tissues and have shown efficacy in animal models of rheumatoid arthritis (RA) 3e8 .
An understanding of in vivo tissue tropism of AAV serotypes is important in the evaluation and application of therapeutic gene delivery. Multiple studies have demonstrated that AAV capsid tropism varies depending on tissue type, species or disease state 3, 6, 9, 10 . In normal rat joints, AAV2 targeted fat pad, ligaments and meniscus while in RA, mostly synovial tissues in the suprapatellar region were transduced 5e8 . Investigation of additional AAV serotypes for gene transfer in RA joints has shown that AAV5-based vectors transduced synovium more efficiently than those with AAV1 and 2 capsids 7 . Evaluation of AAV transduction in equine chondrocytes and synoviocytes in vitro demonstrated that AAV2, AAV3 and AAV6 were superior to AAV1, AAV5 and AAV8 11 . However, in vitro culture conditions rarely mimic cell surface receptor expression and biological barriers presented in in vivo conditions. Currently, no studies evaluating AAV capsids in OA animal models have been reported.
Oxidative stress is elevated in cartilage and synovial tissues in human OA and in animal models of OA and likely contributes to disease amplification by increasing production of inflammatory mediators and matrix degrading enzymes 1,12e14 . The free radical burden by reactive oxygen species (ROS) is further increased by concomitant down-regulation of various anti-oxidant proteins 1, 15, 16 . A recent clinical study also highlighted the role of synovial oxidative stress in OA pathology by revealing a correlation between synovitis and cartilage degradation 17 . Thus, treatment of joints with anti-oxidants may reduce synovial inflammation with potential decrease in cartilage degradation. This was shown by systemic up-regulation of heme oxygenase-1 (HO-1), a protein with anti-oxidant, anti-inflammatory and cytoprotective properties in RA models 18e21 . Though HO-1 has not been tested in OA models, it reduced inflammatory pathways and production of matrix metalloproteases in OA synoviocytes and chondrocytes in vitro 22, 23 .
Our study objectives were to evaluate (1) tissue tropism of recombinant AAV (rAAV) vectors in mouse OA joints after IA delivery, (2) the degree and location of oxidative stress in vivo and its effect on AAV transduction in vitro and (3) the effect of local expression of HO-1 on cartilage degradation. To address the latter, HO-1 gene was delivered by rAAV into the joints of STR/ort mice, a spontaneous model of OA. These mice exhibit many characteristics of human OA including cartilage degradation, lowgrade synovial inflammation, bone remodeling and oxidative stress 1, 13, 14, 24, 25 .
Methods

Construction of rAAV vectors
The LacZ expression plasmid contained a human cytomegalovirus (CMV) promoter, E. coli b-galactosidase (b-gal) gene (LacZ) and a bovine growth hormone (BGH) polyadenylation signal (polyA). The enhanced green fluorescence protein (EGFP) vectors contained CMV enhancer-chicken b-actin (CBA) promoter. Human (h) HO-1 cDNA (OriGene Technologies) was cloned into an expression cassette containing a CMV promoter and an SV40 polyA. A negative control, empty vector (EV) contained non-coding DNA followed by BGH and SV40 polyA. All expression cassettes were cloned as single-stranded vectors into a plasmid pAAVSP70 containing AAV type 2 inverted terminal repeats (ITRs) 26 . AAV recombinant vectors were generated by triple transfection as described 26 . Pseudotyped AAV vectors were obtained by crosspackaging genomes into AAV1, AAV2, AAV5 or AAV8 capsids 10 .
The vectors were purified by iodixanol gradient and resulting vector titers were quantitated by real time Taqman PCR assay (ABI Prism 7700) using primers specific to either BGH or SV40 polyA. Values were expressed as DNAse resistant particles (drps) per ml 27 .
In vitro experiments
Primary synoviocytes were dissected from rabbit knee joints and digested with 0.5 mg/ml collagenase at 37 C overnight in Dulbecco's modified Eagle's media (DMEM). Isolated synoviocytes were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin and 100 mg/ml streptomycin in a 5% CO 2 incubator at 37 C until confluent. and assayed for APF fluorescence by FACS as described above.
Animal studies
Male STR/ort (Harlan Laboratories Inc) and CBA mice (Harlan Laboratories Inc) were housed individually and fed standard irradiated rodent chow and water ad libitum. For serotype evaluation, AAV/LacZ or AAV/1/EV vectors were administered by IA route into stifle joints of 21e26 week-old STR/ort and CBA mice (eight joints/ group; randomized by age). Under appropriate pain medication, the shaved and cleaned joints in a flexed position were injected with 6 ml (3 Â 10 10 drp/joint) of virus using a Hamilton syringe with a 30-gauge needle. Five weeks later, mice were euthanazed by CO 2 asphyxiation. Hind knees were skinned and harvested and the patellar tendon was cut to expose the joint space followed by staining for b-galactosidase activity. For evaluation of HO-1 gene delivery as a therapeutic approach to OA, AAV1/EV and AAV1/HO-1 vectors were injected into joints of 13e15 week-old mice with 5 Â 10 10 drp rAAV/joint (10e12 joints/group; four joints for AAV1/ LacZ) as described above. Animals were sacrificed 3 months later (at 25e27 weeks of age) by cervical dislocation and joints were collected for histological analysis. Studies were approved by the Genzyme Institutional Animal Care and Use Committee (IACUC) and conducted in accordance with humane guidelines for animal care and use.
Joint processing and histological evaluation
For AAV/LacZ studies, skinned joints were tied onto histology cassettes, fixed with 2% PFA in 0.1 M NaHPO 4 , pH 7.4 for 1 h and incubated overnight at 37 C in 1.2 mg/ml solution of 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal; Invitrogen) in PBS containing 5.2 mM potassium ferricyanide, 5.0 mM potassium ferrocyanide, 1 mM magnesium chloride, 0.01% sodium deoxycholic acid (sodium salt) and 0.02% IGEPAL CA-630. All chemicals were from Sigma Aldrich. After staining, joints were rinsed with PBS and fixed in 10% normal buffered formalin (NBF) overnight followed by decalcification in buffered formic acid (trisodium citrate) (Decal, Polyscientific). Samples were embedded into paraffin, sectioned coronally at three levels (100 mm apart) and stained with hematoxylin and eosin (H&E), nuclear fast red or toluidine blue (T. blue). Joints that received AAV1/HO-1 or control vector were fixed for 2 days in 10% NBF, decalcified for 3 days, embedded in paraffin and sections obtained were stained with H&E and T. blue. Evaluation of b-gal positive cells was done from nuclear fast red-stained sections analyzing three different levels. For joint pathology scoring (H&E-and T. blue-stained sections) the section with the most advanced histologic lesions was analyzed using a published scoring system 24 . All evaluations were performed by a board-certified veterinary pathologist. Each analysis contained n ¼ 8e12 STR/ort or CBA joints.
Immunohistochemisty
Tissue sections (5 mm) were processed for immunohistochemistry (IHC) using rabbit polyclonal antibodies to 3-nitrotyrosine (3-NT; 1 mg/ml; Upstate Biotechnology) or to HO-1 (1:100 dilution; Epitomics) as previously described 14 . The signal from biotinylated secondary goat anti-rabbit antibodies was amplified by addition of avidinealkaline phosphatase conjugate (ABC System; Vector Laboratories). The complex was revealed with Vector Red (Vector Laboratories) followed by counterstaining with hematoxylin (Dako). All samples were run simultaneously for each antigen to avoid experimental variation. Isotype controls were used in parallel to confirm the specificity of the staining. The number of 3-NT positive cells was scored using scoring system previously described 14 . 
Statistical analysis
Comparison of quantitative and semi-quantitative in vivo data between multiple groups was performed using non-parametric Fig. 1 . Histopathological scoring of joints from STR/ort and CBA mice at 26e31 weeks of age. Scatter plot shows cartilage scores (H&E-stained sections) for individual joints (filled circles) and group median (horizontal line) (n ¼ 8/group). Scoring was performed as described in Methods. Statistical analysis by KruskaleWallis showed no significant difference between the STR/ort groups while they were significantly different from CBA mice (P < 0.05). KruskaleWallis test with Dunn's multiple comparison post-test using GraphPad Prism statistical software version 5.04 (GraphPad Software, Inc.). Comparison of two groups was done by Manne Whitney t test. In vitro data represented two to three independent observations and were performed minimum of two times. Data was analyzed for 95% confidence intervals (CI) and significance by unpaired Student's t test.
AAV8/LacZ
Results
Localization of AAV transduction in osteoarthritic joints
To evaluate tropism of rAAV serotypes in mouse OA joints, a panel of pseudotyped AAV vectors encoding the LacZ gene was administered directly into the stifle joints of STR/ort mouse. These mice develop spontaneously articular cartilage changes characteristic for OA pathology around 10e20 weeks of age 25 . Histopathological scoring of joints at the time of sacrifice showed that all STR/ ort mice had detectable cartilage surface fibrillations and loss of proteoglycan while cartilage of CBA mice was normal (Fig. 1) . To localize AAV transduction sites, the joints were stained for b-gal activity. Macroscopically, the most widespread staining around the joint space was observed with rAAV1 for STR/ort and CBA mice [ Fig. 2(A) ]. AAV8 strongly transduced muscle tissue surrounding the joint while very little staining was detected with AAV5. Interestingly, a distinctive suprapatellar pouch staining was consistently detected with AAV2 capsid.
To identify transduced cell types in the mouse joint, nuclear fast red-stained sections were scored for b-gal positive cells [ Fig. 2(B) ]. Control AAV1/EV injected joints showed no endogenous b-gal activity while multiple cell types were positive in AAV1/LacZtreated STR/ort mice. These included synoviocytes, adipocytes, joint capsule fibroblasts, skeletal muscle cells and occasionally chondrocytes (mainly at the sites of cartilage remodeling) of OA joints (Fig. 3) . AAV1 transduction was similar in CBA mice except that chondrocytes were not transduced suggesting that OA-related changes may aid AAV1. AAV5 showed a similar localization of transduction but at a lower frequency. In AAV2-treated mice, tissue sections from the suprapatellar region showed b-gal positive cells at the synovial lining while little staining was detected surrounding the joint space. AAV8 exhibited mostly skeletal muscle transduction with no detectable transduction in the synovial tissues.
Synovial oxidative stress and effect on AAV transduction
Oxidative stress is elevated in human OA synovial tissues. To determine the effect of oxidative stress on AAV transduction, we infected primary rabbit synoviocytes with rAAV2 encoding EGFP gene followed by induction of oxidative stress by a brief exposure to H 2 O 2 (rabbit synoviocytes were used since mouse synoviocytes were difficult to obtain in sufficient quantities; AAV2 was used for rabbit cells due to better infection in vitro; data not shown). H 2 O 2 has been detected in OA synoviocytes and generates strong oxidizing agents including peroxinitrite 28 . These conditions enhanced AAV transduction of synoviocytes in a dose-dependent manner and resulted in 10-fold increase of EGFP expression with 100 mM H 2 O 2 [ Fig. 4(A) ]. Generation of oxidizing agents was confirmed using cell permeable ROS sensitive fluorescein dye (APF) that reacts with hydroxyl radicals and peroxynitrite anions and upon oxidation exhibits elevated green fluorescence [ Fig. 4(B) ] 29 .
Synoviocyte viability was not reduced by 100 mM H 2 O 2 -treatment as measured by trypan blue staining while higher concentrations of H 2 O 2 resulted in cell toxicity (not shown).
We next investigated the level of oxidative stress in STR/ort OA joints and its correlation to AAV transduction sites in OA joints. The localization and intensity of oxidative stress was evaluated by immunostaining for 3-NT, a marker for nitrosative and oxidative stress. 3-NT modifications of cellular proteins are generated by reaction with peroxynitrite (ONOOe), a reactive oxidant that forms in the presence of nitric oxide and superoxide 12 . A significant increase in the number of 3-NT positive cells was observed in the synovium of STR/ort mice compared to OA-resistant CBA mice (Fig. 5) . Increase in 3-NT staining was also detected in periosteum while the number of 3-NT immunopositive cells in the cartilage, ligaments and meniscus was not significantly increased compared to that in CBA joints. Thus, the synovium of STR/ort mice exhibits significantly elevated levels of oxidative stress that can potentially increase AAV transduction in these cells.
AAV1-mediated HO-1 gene transfer into osteoarthritic joints
The above studies indicate that AAV1 is best suited for transduction of mouse OA joint and that there is an increased oxidative Fig. 6(B) ].
To evaluate the efficacy of AAV1/HO-1 in the mouse OA model, the vector was administered directly into the joints of STR/ort mice at 3e4 months of age (dose similar to AAV/LacZ studies). Three months later, the effect of local HO-1 expression in the joints on cartilage degradation was analyzed by scoring the articular cartilage for surface changes (H&E-stained sections) and for proteoglycan content (T. blue-stained sections). The results showed cartilage degradation in all the negative controls (AAV1/EV-treated) and naive STR/ort mice mice compared to OA-resistant CBA mice (Fig. 7) . However, administration of AAV1/HO-1 into the STR/ort joints did not significantly reduce cartilage pathology compared to AAV1/EV-treated mice. No differences were observed in the synovial inflammation or proliferation scores indicating that IA delivery of rAAV1 vector did not affect synovial pathology (Fig. 7) . No treatment-related adverse effects were observed in these studies (in bodyweight gain or mortalities).
Since no efficacy was observed by the AAV1/HO-1 treatment, we analyzed transduction efficiency of rAAV1 vectors by an IHC assay to detect HO-1 or by X-gal staining (in AAV1/LacZ-administered joints tested in parallel). Since specific detection of vectormediated production of human HO-1 by IHC was not possible due to lack of human-specific HO-1 antibodies, the overall HO-1 levels in the joints were evaluated using an antibody that crossreacts with human and mouse HO-1. The results showed a significant increase in the synovial HO-1 expression in AAV1/EV-treated STR/ort joints compared to CBA joints [ Fig. 8(A and B) ]. Due to the robust endogenous, disease-induced HO-1 expression in STR/ ort mice, we were unable to measure any increase in HO-1 levels in AAV1/HO-1-treated mice. However, AAV1/LacZ-treated joints showed detectable b-gal activity in the synovial tissues 3 months post-delivery therefore supporting successful rAAV-mediated gene transfer in this experiment [ Fig. 8(C) ].
Discussion
Treatment of an osteoarthritic joint by local production of a therapeutic agent is an attractive treatment strategy for OA. In this report, we demonstrate that AAV-based vectors allowed gene delivery into mouse OA joints. Our studies also highlighted a strong elevation of oxidative stress in the synovial lining of the joint and the benefit of even a low level of oxidative stress to enhance transduction of AAV vectors. We were, however, unable to observe any significant improvement from local expression of HO-1, an antioxidant protein, on OA cartilage pathology indicating that this delivery method or timing of the treatment was not sufficient to reduce the progression of pre-existing disease in the STR/ort model. AAV vectors are useful tools for both systemic and localized delivery of therapeutic genes due to their low inflammatory nature and their ability to confer persistent transgene expression 3e9, 26, 27 . They have also been tested in human joints in a clinical trial where rAAV2 vectors were delivered intra-articularly into RA patients and were well tolerated with no major safety issues 30, 31 . To evaluate rAAV vectors in animal models, the choice of capsid serotype is of importance as the tissue tropism of AAV vector is affected by AAV capsid serotype, species of the model as well as disease-induced changes 3, 6, 7, 9, 10 . No previous studies have analyzed AAV transduction in vivo in mouse OA joints where the synovium generally exhibits only low and intermittent inflammation compared to RA joints 13, 14 . Based on our results, the use of AAV1 capsid resulted in the most robust transduction of mouse OA joint providing gene transfer to multiple cell types including synovial lining whereas AAV5, AAV8 and AAV2 were not as efficient. Contrary to these results, others have reported that rAAV5 is the optimal serotype for transduction of synovial lining in mouse models of RA with some transduction occurring with AAV2 as well 5e8 . Currently it is unclear whether the serotype differences in joint transduction reflect disparities in the disease pathology or AAV receptor levels between the models. Both AAV1 and AAV5 bind cell surface N-linked a2,3 and a2,6 sialic acids as primary attachment receptor unlike AAV2 which utilizes heparin sulfate proteoglycans for attachment 32e34 .
AAV1 is also known to efficiently transduce mouse muscle as was seen in our data as well as human polarized airway epithelial cells 9, 10, 35 . We observed very little in vivo gene transfer to mouse chondrocytes by any of the AAV vectors tested. In vitro, transduction of human and rabbit chondrocytes by AAV2 vectors has been reported but this likely reflects differences in biological barriers between in vitro and in vivo conditions 36, 37 . Similarly, local rAAV vector delivery demonstrated limited access into subchondral bone precluding these vectors for treating the OA bone pathology that likely contributes to cartilage degradation.
The impact of disease environment on AAV transduction has been previously demonstrated in joint diseases. In mouse models of RA with a chronic inflammatory milieu in the joints, both higher levels and better persistence of AAV transduction were observed in RA compared to non-arthritic joints 6 . The beneficial effect of inflammation on AAV transduction was also supported by increased synovial fibroblast transduction by addition of inflammatory cytokines in vitro and by lipopolysaccharide (LPS)-treatment in vivo 38, 39 .
Our in vitro data indicated that even low level of oxidative stress augmented AAV transduction as this was achieved without reducing cell viability or inducing endogenous HO-1 stress response. Since the level of oxidative stress controlled the magnitude rAAV transgene expression in vitro, it may provide analogous disease-inducible regulation of transgene production preferentially at the sites of oxidative stress in vivo. Enhanced AAV transduction has also been reported following UV irradiation and chemotherapy, conditions that are likely to increase oxidative stress 40 . While oxidative stress has been reported in STR/ort joints, we demonstrated here elevated levels of peroxynitrite modified proteins indicative of reactive oxygen and nitrogen species in the synovial lining of the joints 13, 14 . Previously, we have observed another indicator of oxidative stress, advanced glycation endproducts (AGEs), also strongly increased in the synovium of these mice 14 . Both the reactive oxygen and nitrogen species and their products induce stress signaling, apoptosis and inflammatory pathways such as NF-kB, MAPK and ERK1/2 in OA that result in elevation of inflammatory cytokines and cartilage degrading proteases 1, 12, 25 . The significance of these pathways in OA pathology were supported by studies using RNA-mediated interference of the NF-kB pathway that slowed-down the progression of OA in a surgical model of rat OA 41 . Synovial oxidative stress and inflammation were also recently reported to be predictive both for OA pain and cartilage degradation in human OA patients 17 . Thus, synovial oxidative stress represents an attractive target for therapeutic intervention to test its role as a driver of OA pathology.
HO-1 exhibits multiple beneficial properties including antioxidant, anti-inflammatory and cytoprotective functions and is often endogenously induced by various stress stimuli 18, 19, 43, 44 . It has been detected in human OA synovium, cartilage and synovial fluids 42e44 . In both OA and RA animal models in vivo, systemic induction of HO-1 by pharmacological agents reduced inflammation and disease pathology 20, 21, 45 . In vitro, HO-induction in OA chondrocytes enhanced cell viability and anabolic processes while it reduced apoptosis and catabolic processes such as matrix metalloprotease (MMP) and prostaglandin production 22 . Similarly, HO-1 expression in osteoarthritic synoviocytes after lentiviral vector delivery down-regulated MMP-1 and -2 production and reduced translocation of HMGB-1, a mediator of synovitis 23 . All of these inflammatory markers and MMPs are elevated in the joints of STR/ ort mice 1, 14, 24 . However, in contrast to HO-1 benefits in systemic or in vitro settings, our data showed that the local production of HO-1 in the diseased joints did not reduce cartilage degradation in the mouse OA model. Instead, we detected endogenous elevation of HO-1 levels in the synovial tissues from OA mice similar to observations on increased HO-1 in synovial joint tissues from human OA and RA patients 42e44 . The synovial HO-1 was likely induced by the strong nitrosative and oxidative stress detectable already at 5 weeks of age in these mice 13, 14, 46 . Peroxynitrite-induced HO-1 expression has also been observed in articular chondrocytes and other cell types in vitro 47, 48 . Though the highly oxidative milieu was beneficial for AAV transduction, it is unknown how it affects the function of locally produced proteins. Both glycation and tyrosine nitration modified proteins are present in the synovium of these mice 14 . Additional studies would be required to determine whether Fig. 7 . Cartilage evaluation after local delivery of AAV1/HO-1 into mouse OA joints. rAAV vectors were administered by IA route into mouse joints at 3e4 months of age and articular cartilage morphology was analyzed 3 months later. H&E-stained sections were scored for cartilage degradation, synovial inflammation and synovial proliferation. T. blue-stained sections were scored for cartilage proteoglycan content. Scatter plot (n ¼ 8e12/group) shows cartilage scores for individual joints (filled circles) and group median (horizontal line) as described in Methods. Statistical analysis by KruskaleWallis showed no difference between the STR/ort groups while they were all different from CBA mice (P < 0.05).
the tyrosines in the vector encoded human HO-1 protein were subject to modifications in vivo as suggested by the inactivation of catalytic activity of HO-1 by peroxynitrite in vitro 49 . Alternatively, our lack of efficacy with HO-1 may suggest that active treatment in models during ongoing disease is likely to be a higher hurdle than more commonly used prophylactic in vivo or in vitro models. In summary, the present study demonstrates that mouse synovial tissues are amenable to transduction by rAAV1 after delivery into the joint space. We also showed significantly elevated levels of the oxidative stress in synovial lining which is likely to increase AAV-based vector transduction in vivo thus making synovial lining cells into disease-inducible depot organs for local therapeutic protein production. However, the local production of HO-1 was not sufficient to reduce articular cartilage degradation suggesting either a minor role of synovial oxidative stress on OA cartilage pathology or issues in therapeutic protein synthesis and function in the highly oxidative environment. Furthermore, the limited access of current AAV vectors by IA delivery to areas such as chondrocytes and subchondral bone may represent a challenge in their utility for delivery of therapeutics designed to improve cartilage viability and repair necessary for the treatment of OA.
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